文献库搜索 | GeneLibs

Li(C),Yin(J),Abel(ML),Solivan(DSV),Bhadres... medRxiv 2026-01-09

...BRCA2 as potential drivers, demonstrating clonal concordance with circulating tumor DNA from the original patient donor....

Brand(F),Rose(LS),Akbarzadeh(AH),Weber(CAM... Acta Neuropathol 2026-01-17

...BRCA2, PMS2, POLE. ATM GVs (n = 6) preferentially predisposed to IDH-mutant astrocytoma (P = 0.007) in patients that wer...

Metcalfe(KA),Kinney(AY),Narod(SA),Poll(A),... Hered Cancer Clin Pract 2026-01-17

...BRCA2 PV between the ages of 35 and 70 years old, who had not elected for RRSO at least 12 months after receipt of genet...

Samigatova(A),Altaeva(N),Suleimenov(Y),Sib... Sci Rep 2026-01-17

...BRCA2, and 51 for BRCA-negative patients. Advanced disease (stages III-IV) was more common among mutation carriers (p < ...

Mack(M),Tufino(AC),Jamalruddin(MA),Dey(S),... Pediatr Blood Cancer 2026-03-00

...BRCA2 (PALB2) in a patient with a late EwS relapse. Its impact on homologous recombination is demonstrated, and breast c...

Liu(D),Fan(Z),Zhang(T),Li(X),Ming(C),Wu(J)... BMC Cancer 2026-01-19

...BRCA2 rs15869, XRCC4 rs2035990 and XRCC5 rs2440 were detected and analyzed in a CRC case-control study (cases (202) and ...

Pradutchon(S),Pithukpakorn(M),Poonyakanok(... Eur J Cancer Prev 2026-09-01

Germline BRCA1 and BRCA2 pathogenic and likely pathogenic variants (PVs) significantly increase the risk of breast cance...

Khatri(L),Fraker(J),Pruthi(S) Maturitas 2026-03-00

...BRCA2 are the predominant genetic contributor, conferring a lifetime risk of ~7%, while BRCA1, CHEK2 and PALB2 variants ...

Sherman(ME),Pacheco-Spann(L),Friedman(S),R... Gynecol Oncol 2026-03-00

To survey knowledge, preferred information sources, and risk tolerance for EC among BRCA1 and BRCA2 pathogenic variant (...

McVey(JC),Wattenberg(MM),Coho(H),Infante(K... Sci Rep 2026-01-31

...Brca2-mutated PDAC. The model demonstrated high sensitivity to cisplatin plus gemcitabine, but limited efficacy of PARPi...